Global Cancer Gene Therapy Market Expected to Reach $2,082 Million by 2023 - Allied Market Research

Tuesday, October 10, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

PORTLAND, Oregon and PUNE, India, October 10, 2017 /PRNewswire/ --

According to

a new report published by Allied Market Research, titled, "Cancer Gene Therapy Market: Global Opportunity Analysis and Industry Forecast, 2017-2023," the Global
Cancer Gene Therapy Market accounted for $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. North America is the highest contributor in the cancer gene therapy market in 2016; however, Asia-Pacific is expected to witness the highest growth rate.

Cancer gene therapy is an approach for the cancer treatment, where genetically engineered vectors such as viruses are used to transfer or replace a mutated gene (that is causing cancer) with a heathy gene. This technique can be used for both the prevention and treatment of disease. The most commonly used techniques for the treatment using cancer gene therapy includes oncolytic virotherapy, gene transfer, and gene-induced immunotherapy.

Do Enquiry for Sample Report@ https://www.alliedmarketresearch.com/request-sample/2605

The rise in prevalence of cancer, ethical acceptance of gene therapy for cancer treatment, and the advancement in this field drive the market growth. In addition, benefits of cancer gene therapy over conventional cancer therapies, increase in government support, and rise in biotechnological funding that encourage the R&D activities for cancer gene therapy fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.

Among the therapy segment, oncolytic virotherapy segment is the largest contributor toward the market growth and gene transfer therapy segment is anticipated to be a lucrative market due to the positive results for these therapies during the preclinical and clinical trials for the treatment of cancer.

In 2016, North America accounted for maximum contribution to the total revenue generated, owing to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with cancer gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.

Do Enquiry before purchasing [email protected] https://www.alliedmarketresearch.com/purchase-enquiry/2605

KEY FINDINGS OF THE STUDY 

  • Gene transfer segment is projected to grow at the highest rate during the analysis period.
  • Oncolytic virotherapy segment generated the highest revenue, and is expected to continue its dominance in the future.
  • North America dominated the global cancer gene therapy market, and is projected to continue its dominance in future.
  • China is expected to grow highest in the Asia-Pacific region.
  • Asia-Pacific is expected to be the fastest growing segment during the forecast period.

The key companies profiled in the report include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Popular Reports by Allied Market Research: 

U.S IVF Services - Opportunity Analysis and Industry Forecast, 2014-2022

Artificial Intelligence in Healthcare Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Forensic Technology Market - Global Opportunity Analysis and Industry Forecast, 2016-2023

About Us: 

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact: Dhananjay Potle 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: +1-800-792-5285 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-020-66346060 Fax: +1?855?550-5975 [email protected]

Web: https://www.alliedmarketresearch.com

SOURCE Allied Market Research



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook